QOL Outcomes Stable With Neurostimulation in Parkinson Disease
By Elana Gotkine HealthDay Reporter
MONDAY, Jan. 22, 2024 -- For patients with Parkinson disease (PD), differences in quality of life (QOL) outcomes are seen with deep brain stimulation of the subthalamic nucleus (STN-DBS), according to a study published online Jan. 18 in JAMA Network Open.
Stefanie T. Jost, Ph.D., from the University of Cologne in Germany, and colleagues examined the long-term effects of STN-DBS versus standard-of-care medication (MED) on QOL in a prospective observational, quasi-experimental trial involving patients with PD. Overall, 108 patients underwent propensity score-matching (62 in the STN-DBS group and 46 in the MED group), resulting in a well-balanced matched subcohort with 25 patients in each group.
The researchers found that Parkinson's Disease Questionnaire 8 (PDQ-8) and activities of daily living (ADL) worsened only in the MED group at five-year follow-up (PDQ-8 change, −10.9; ADL change, −2.0), while in the STN-DBS group, both outcomes remained stable. There was a moderate correlation observed for changes in PDQ-8 and ADL. STN-DBS outcomes were favorable for motor complications, mobility, and levodopa-equivalent daily dose reduction (mean differences in change scores between STN-DBS and MED, −2.0, −1.0, and −821.4, respectively).
"These findings may provide helpful information when counseling patients on the efficacy of STN-DBS for PD and monitoring patients postoperatively in long-term follow-up," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.